TD Cowen named Twist Bioscience a “best idea for 2024.” While the stock trades in line with peers, the firm believes Twist is both “oversold” and “poised to outperform” given what it calls “very conservative guidance” in addition to multiple tailwinds in FY24. The firm sees visibility into its path to profitability and points to FY24 catalysts that include new product launches and margin improvements as “Factory Of The Future” work scales. The firm keeps an Outperform rating and $33 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TWST:
- Twist Bioscience price target raised to $30 from $26 at Barclays
- Twist Bioscience price target raised to $32 from $26 at Evercore ISI
- Twist Bioscience sees FY24 revenue $285M-$290M, consensus $298.67M
- Twist Bioscience sees Q1 revenue $67M-$68M, consensus $63.45M
- Twist Bioscience reports Q4 EPS (81c), consensus (92c)